The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes artwork

Life Sciences · BZ Group

The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

by BZ Group

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts, deal intelligence, and the daily newsletter at https://thepharmacloseout.com/. Host voices are AI-created.

Latest episodes

Showing 20 · updated from the feed

Daily Roundup | Celldex Ends Eczema Program & Revolution Medicines Updates Pancreatic Cancer Data (Delayed Nov. 19)

Delayed edition for Thursday, November 19, 2026. Celldex says it is ending barzolvolimab development in atopic dermatitis after its Phase 2 trial missed the primary itch

Nov 20
6 min

Daily Roundup | Pfizer’s $330M Upfront CAR-T Bet & Infilbray Approved for Type 3 Gaucher Neurologic Symptoms

Pfizer commits $330 million upfront to license three autoimmune CAR-T programs from Starna Therapeutics before human trials — the lead in this delayed November 18 edition

Nov 20
11 min

SELLAS' AML Survival Win Sets Up Its FDA Push & Isomorphic Raises $5B

SELLAS reports median survival of 24.0 months with its vaccine versus 14.7 with investigator-chosen care in REGAL, a Phase 3 trial in later-remission AML; we unpack the f

Nov 18
12 min

Daily Roundup | J&J to Buy Ollin for $2.2B Upfront & Roche’s Wilserdly Combo Approved for Breast Cancer

In this delayed Monday closeout, Johnson & Johnson agreed to buy Ollin Biosciences for $2.2 billion upfront, and Blackstone agreed to fund Phase 3 work on OLN324 in wet A

Nov 17
11 min

Week in Review | Summit's FDA Setback, Novo's Obesity Data & Pfizer's Blackstone Deal

Delayed Sunday, November 15 edition. Summit says the FDA issued a complete response letter for ivonescimab plus chemotherapy in previously treated EGFR-mutated lung cance

Nov 16
46 min

Daily Roundup | Imfinzi + Padcev Add Bladder Surgery Option & Rezolute: 12 of 16 Stop IV Glucose in Preliminary Data

The FDA approved Imfinzi (durvalumab) plus Padcev (enfortumab vedotin-ejfv) before bladder removal, then Imfinzi alone afterward, for adults with muscle-invasive bladder

Nov 14
13 min

Daily Roundup | enGene Plans Bladder Cancer Filing & Mirum’s Second Hepatitis D Phase 3 Win

enGene plans to start its FDA filing for detalimogene voraplasmid in bladder cancer by year-end after longer follow-up in a single-arm trial. Mirum’s brelovitug met the p

Nov 13
8 min

Daily Roundup | Bayer's Stroke Approval Puts Bleeding Risk in Focus & Beam Nears Sickle Cell Filing

Delayed release of the November 10, 2026 edition. News reflects the November 10 research cutoff. Bayer's Sunharbo (asundexian) wins FDA approval for stroke prevention, w

Nov 12
12 min

Week in Review | Vir's Hepatitis Delta Result & CVS Split Plan: Full Recap

In this full November 2–8 recap, 44% of treated patients in Vir's hepatitis delta trial met the Phase 3 primary endpoint, with an important difference in when the compari

Nov 10
48 min

Daily Roundup | ANI's Recommended Egetis Offer & BHB-1893 Heart Study: Most End on Starting Dose

ANI Pharmaceuticals made a recommended cash offer of about 5.3 billion kronor for Egetis Therapeutics, maker of Emcitate (tiratricol); the acceptance period is expected t

Nov 7
9 min

Daily Roundup | Rybrevant Faspro Gets Accelerated FDA Nod in Head and Neck Cancer & Tibsovo Lifts EFS in Fit AML

J&J's Rybrevant Faspro (amivantamab) won accelerated FDA approval in later-line head and neck cancer on a 42% single-arm response rate. A HOVON trial adding Tibsovo (ivos

Nov 7
14 min

Daily Roundup | CVS plans to split pharmacies from Aetna and Caremark & AbbVie licenses Nxera's IBD drug

CVS Health plans to split into two public companies, separating about 9,000 pharmacies from Aetna and Caremark, targeting the first half of 2028. This delayed November 4

Nov 7
9 min

Daily Roundup | Fresenius gains access to up to 37 biosimilar candidates via WuXi & Supernus-Indivior merger closes

Fresenius gains exclusive access to up to 37 biosimilar candidates through WuXi Biologics, with initial development expected on biosimilars of polatuzumab vedotin and tep

Nov 7
9 min

Daily Roundup | Servier Drug Misses Becker Trial & Karyopharm Files Chapter 11

Servier's sevasemten missed its pivotal Becker muscular dystrophy trial, while Karyopharm filed Chapter 11 and proposed an Ayrmid deal around XPOVIO. This delayed Novembe

Nov 5
11 min

Week in Review | Estrogen Patch Boxed Warnings Revised, Novartis Writes Down Del-Desiran & Acumen Ends Sabirnetug

November 1, 2026 edition — delayed release. This recap covers October 26–30; its dated week-ahead items reflect preparation-time previews, not subsequently reported resul

Nov 3
37 min

ESMO 2026 Debrief: A 12-Week Checkpoint Dosing Trial Stopped Early & Ivonescimab Beats Imfinzi on Survival in Biliary Cancer

The Pharma Closeout's ESMO 2026 Debrief brings you the readouts from the European Society for Medical Oncology congress in Madrid that matter, what they change, and what

Nov 2
20 min

Daily Roundup | Acumen Ends Alzheimer's Antibody After Phase 2 Miss & Inovio's Voceryq Wins Accelerated Approval

October 30 edition — delayed release on November 1. References to today and Friday in the audio refer to October 30. Acumen ends sabirnetug after a Phase 2 Alzheimer's t

Nov 1
12 min

Daily Roundup | Iovance Lung Data Points to a Subgroup & Ono Plans New Pain Studies After 3 Misses

October 29, 2026 edition, released October 30. The audio reflects the October 29 roundup; the INO-3107 watch refers to an October 30 FDA target date, not an announced dec

Oct 30
14 min

Daily Roundup | Genmab's Cancer Survival Gain & Lilly's Retatrutide Dose Trade-Off

This is the October 28 edition of The Pharma Closeout, released October 29. Genmab's investigational petosemtamab combination improves survival against pembrolizumab alo

Oct 29
10 min

Daily Roundup | Artiva Ends AlloNK, Cuts 94% of Staff & Ferring Agrees to Buy Gameto

Artiva ends AlloNK and cuts about 94% of staff after a risk-benefit review covering durability and two separately assessed deaths. Ferring agrees to acquire Gameto for up

Oct 28
10 min

Chart trend

Position in the Life Sciences chart (US), last 90 days.

#22
all-time peak
50
days in the top 50 since Mar 2026

Chart positions

Where The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes ranks today in each Apple Podcasts chart (US, Nov 21, 2026).

#76 ▼ 7 Life Sciences US

More podcasts like The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

Popular shows in Life Sciences, for your next listen.

Browse charts by category

Daily updated Apple Podcasts rankings for the United States.

About The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes on Reason.fm

Here you find the Apple Podcasts chart positions of The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes, its latest episodes to listen to directly, and reviews from listeners. Rankings are updated daily for the United States.

Contact

Questions or issues? Reach us at hello@reason.fm

0:000:00